On May 20, PegBio Co Ltd (02565.HK) rose 8.37% in regular trading, trading at HK$17.56/share with trading volume of HK$77.81 million, extending a multi-day rally following a surge of over 100% on May 18.

The sustained upward momentum is driven by the company's strategic commercialization partnership with Tengrui Pharmaceutical for Paidakang (维培那肽注射液/PB-119), a long-acting GLP-1 receptor agonist approved in November last year. Under the agreement announced in March, Tengrui Pharmaceutical secured exclusive mainland China commercialization rights, committing approximately HK$140 million in upfront payments and targeting cumulative sales exceeding RMB 10 billion. Additionally, on May 12, Fangzhou Jiankei and Tengrui signed a strategic cooperation to launch Paidakang on its internet hospital platform as a nationwide online debut, further catalyzing investor enthusiasm.

PegBio is a China-based biopharmaceutical company focused on innovative therapies for chronic and metabolic diseases, with a pipeline spanning type 2 diabetes, obesity, and NASH.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)